Intech Biopharm Ltd.

Intech Biopharm Ltd. (益得生物科技股份有限公司) is a Taiwanese specialty pharmaceutical company founded in 2010 as a subsidiary of Synmosa Biopharma Corporation. Headquartered in Taipei, the company focuses on the research, development, and manufacturing of generic drugs and new drugs for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as well as oncology. Its core technological advantage is the HFA MDI (hydrofluoroalkane metered-dose inhaler) platform, which is described as the only one of its kind in Taiwan and one of the few globally. The company also develops dry powder inhalers (DPI) and has proprietary formulation technologies such as iLEF® (Intech Low Ethanol Formulation). Intech Biopharm's product pipeline includes new combination drugs, new dosage forms, and high-barrier generics, with products like Duasma, Synvent, Synflutide, and others. The company obtained its first product licenses in Taiwan in 2013 and has since expanded its patent portfolio and received government grants and awards. In 2018, it listed on the Taipei Exchange (OTC market). Intech Biopharm positions itself as an innovative, quality-driven, and patient-caring pharmaceutical developer, aiming to bring high-quality inhalation therapies to international markets.

Intech Biopharm Ltd. was established in 2010 as a subsidiary of Synmosa Biopharma Corporation, a Taiwanese pharmaceutical company. The origins of its core technology date back to 2007, when Synmosa set up an HFA MDI research and development division (研二处) and converted a CFC MDI production line purchased from Boehringer Ingelheim to an environmentally compliant HFA MDI line. This laid the foundation for Intech Biopharm's specialized focus on inhalation drugs. In 2012, the company obtained a US patent for its spray counter (喷雾计数器). The following year, 2013, was pivotal: Intech Biopharm received qualification for incentives under the Act for the Development of Biotech and New Pharmaceuticals from the Ministry of Economic Affairs; its product Duasma won a Silver Award for Pharmaceutical Technology Research and Development from the Ministry of Health and Welfare and the Ministry of Economic Affairs; Duasma and Synvent obtained Taiwan drug licenses, and Duasma was launched. Additionally, patents were granted in China for the spray counter and in Taiwan for a process for preparing metered-dose inhalers for treating respiratory diseases. The company also began receiving external investment. In 2014, Intech Biopharm obtained a Chinese patent for an inhaled combination composition for asthma. It increased its capital to NT$550 million, with Synmosa holding about 50% equity. The company went public and registered on the Emerging Stock Market (兴柜) in mid-2014. It also moved from rented laboratories at the Development Center for Biotechnology to newly purchased experimental offices and recruited more talent. In 2016, after a cash capital increase, the company's capital reached NT$700 million, and it passed the Ministry of Economic Affairs' review for OTC listing as a technology enterprise. In 2017, it completed construction of a dedicated inhalation (MDI & DPI) manufacturing facility compliant with European and American standards and began trial production. In 2018, Intech Biopharm listed its shares on the Taipei Exchange (股票上柜). Since then, the company has continued to develop its pipeline of respiratory and oncology drugs, leveraging its HFA MDI and DPI platforms. It holds multiple domestic and international patents and drug licenses and remains committed to innovation, quality, professionalism, and care.

• 2018

  Listed on Taipei Exchange (OTC).

• 2017

  Completed construction of MDI & DPI dedicated plant compliant with European and American standards; began trial production.

• 2016

  Capital reached NT$700 million after cash increase; passed MOEA review for OTC listing.

• 2014

  Obtained Chinese patent for inhaled combination composition; capital increased to NT$550 million; Synmosa held ~50%; public offering and registration on Emerging Stock Market.

• 2013

  Received biotech new drug development incentive; Duasma won Silver Award; Duasma and Synvent obtained Taiwan drug licenses; Duasma launched; patents in China and Taiwan.

• 2012

  Obtained US patent for spray counter.

• 2010

  Intech Biopharm Ltd. founded as a subsidiary of Synmosa Biopharma.

• 2007

  Synmosa Biopharma established HFA MDI research division and converted CFC MDI line to HFA MDI.

Specialty pharmaceutical company with a unique inhalation technology platform, focusing on high-barrier generics and innovative respiratory drugs for international markets.

• Duasma (Budesonide)

  Inhaled corticosteroid for asthma, launched in 2013 in Taiwan.

• Synvent (Albuterol/Salbutamol)

  Short-acting beta agonist bronchodilator, obtained Taiwan drug license in 2013.

• Synflutide (Fluticasone+Salmeterol)

  Combination inhaler for asthma/COPD.

• SYN006 (Budesonide+Formoterol)

  New combination drug in development.

• SYN007 (Tiotropium)

  New dosage form in development.

• SYN010 (Synbufo, Budesonide+Formoterol)

  High-barrier generic in development.

• SYN011 (Albuterol/Salbutamol)

  High-barrier generic in development.

1. 1Official Website Homepageintechbiopharm.com
2. 2About Usintechbiopharm.com
3. 3Products & R&Dintechbiopharm.com
4. 4Company Historyintechbiopharm.com
5. 5Wikidatawikidata.org